Related Experiment Video

Updated: Dec 3, 2025

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.3K

Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19

Qingyang Zhong1, Jie Peng1

  • 1Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Journal of Clinical Laboratory Analysis
|October 31, 2020
PubMed
Abstract

Insights

High platelet mean volume/platelet count ratio (MPR) is an independent risk factor for developing severe pneumonia in COVID-19 patients. This finding highlights MPR as a potential predictive marker for disease severity in novel coronavirus infectious disease 2019.

Area of Science:

  • Medical research
  • Hematology
  • Infectious diseases

Background:

  • Platelet mean volume/platelet count ratio (MPR) is recognized as a marker for inflammatory and infectious conditions.
  • The association between MPR and COVID-19 severity, specifically severe pneumonia, remains incompletely understood.

Purpose of the Study:

  • To investigate the relationship between MPR and the incidence of severe pneumonia (SP) in COVID-19 patients.
  • To determine if MPR serves as an independent risk factor for SP in COVID-19.

Main Methods:

  • Retrospective analysis of 85 COVID-19 patients, categorized into low and high MPR groups.
  • Generalized estimating equations for repeated measures and Cox regression with inverse probability of treatment weighting (IPTW) for bias reduction.
  • Assessment of MPR's impact on the incidence of severe pneumonia (SP) as the primary outcome.

Main Results:

  • Patients who developed SP exhibited significantly higher MPR levels at baseline and during the initial days post-admission compared to mild cases.
  • The high MPR group demonstrated a significantly higher incidence of SP (log-rank test P = .001).
  • Adjusted Cox regression and IPTW analyses confirmed high MPR as an independent risk factor for SP (HRs > 5.8, P < .009).

Conclusions:

  • Elevated MPR levels are independently associated with an increased risk of developing severe pneumonia in COVID-19 patients.
  • MPR can be considered a significant predictive biomarker for COVID-19 progression to severe pneumonia.
Keywords:
COVID-19inflammationnovel coronavirus pneumoniaplatelet mean volume/platelet count ratiosevere pneumonia

More Related Videos

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.6K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.9K

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
662
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.1K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
565
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
624
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.5K
Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
822